← Back to Search

GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination

Empagliflozin 25 MG + Liraglutide 1.8 MG for Type 2 Diabetes (NATRIURETIC Trial)

Phase 2
Recruiting
Led By David ZI Cherney, MD PhD FRCPC
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up outcome will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)
Awards & highlights

NATRIURETIC Trial Summary

This trial studies how two diabetes treatments affect heart health in people with type 2 diabetes without heart failure.

Eligible Conditions
  • Type 2 Diabetes

NATRIURETIC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~glomerular filtration rate (gfr, based on plasma iohexol clearance) will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and glomerular filtration rate (gfr, based on plasma iohexol clearance) will be measured at 2 time points: monotherapy (6 weeks) and combination therapy (12 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proximal tubular natriuresis
Secondary outcome measures
Arterial stiffness
Body weight
Glomerular Filtration Rate
+4 more

NATRIURETIC Trial Design

2Treatment groups
Experimental Treatment
Group I: LiraglutideExperimental Treatment2 Interventions
Liraglutide Subcutaneous Total Dose 1.8mg daily for 6 weeks
Group II: EmpagliflozinExperimental Treatment2 Interventions
Empagliflozin Tablets Total Dose 25mg daily for 6 weeks

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,489 Previous Clinical Trials
489,728 Total Patients Enrolled
David ZI Cherney, MD PhD FRCPCPrincipal InvestigatorUniversity Health Network, Toronto General Hospital
1 Previous Clinical Trials
50 Total Patients Enrolled

Media Library

Empagliflozin 25 MG + Liraglutide 1.8 MG (GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination) Clinical Trial Eligibility Overview. Trial Name: NCT04535960 — Phase 2
Type 2 Diabetes Research Study Groups: Liraglutide, Empagliflozin
Type 2 Diabetes Clinical Trial 2023: Empagliflozin 25 MG + Liraglutide 1.8 MG Highlights & Side Effects. Trial Name: NCT04535960 — Phase 2
Empagliflozin 25 MG + Liraglutide 1.8 MG (GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04535960 — Phase 2
~6 spots leftby Jun 2025